GU Cancers 2026 | RAMPART: PROs with durvalumab and tremelimumab in RCC
Sophie Merrick, MBCHB, MRCP, University College London, London, UK, discusses patient-reported outcomes from the RAMPART trial (NCT03288532) comparing durvalumab plus tremelimumab versus active monitoring in resected renal cell carcinoma. At week 16, the treatment arm experienced worse quality of life across multiple domains including overall health, fatigue, and insomnia, reaching clinically meaningful thresholds. By month 15, most effects improved, though pain and cognitive function remained worse. This interview took place at the 2026 ASCO GU Cancers Symposium in San Francisco, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
RAMPART is an investigator-led international phase three trial, which is evaluating adjuvant durvalumab alone or in combination with tremelimumab in resected renal cell carcinoma. And that combination of durvalumab and tremelimumab has already shown disease-free survival benefit, but obviously any treatment needs to be evaluated for its impact on quality of life. And so we had an optional sub-study embedded within Rampart and the patient-reported outcomes from that to what we’re presenting at GU ASCO...
RAMPART is an investigator-led international phase three trial, which is evaluating adjuvant durvalumab alone or in combination with tremelimumab in resected renal cell carcinoma. And that combination of durvalumab and tremelimumab has already shown disease-free survival benefit, but obviously any treatment needs to be evaluated for its impact on quality of life. And so we had an optional sub-study embedded within Rampart and the patient-reported outcomes from that to what we’re presenting at GU ASCO. Just to tell you, first of all, when we measured the quality of life. So we did that at baseline, at week 16 and at month 15, and we evaluated a number of different areas. So overall health and quality of life, the five different functional domains and nine symptoms and single item scales. In terms of those two different time points, we saw different things. So at that early phase at week 16, we saw a worsening in quality of life, kind of across the board, but the clinically significant and statistically significant findings were worsening in overall health and quality of life, role functioning, fatigue and insomnia. And then at month 15, those largely improved, but we did see some new late emerging effects in self-reported cognitive function and also in pain as well.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
